{"acquisitions":[],"changes":[],"country":"US","description":"Solve Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for solid tumors. It serves patients with cancers driven by selectively expressed tumor antigens, with leads SLV-154 and SLV-324 in Phase 1 trials. Its CloakLink hydrophilic linker improves ADC stability and widens the therapeutic window.","domain":"solvetx.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego, United States","multiples":[],"name":"Solve Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":120000000,"connectionsAmong":[],"currency":"USD","date":"2025-11-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"solvetx-com-2025-11-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},"status":"attributed","type":"series-d+","url":null}],"slug":"solvetx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},{"fact":"existence","publisher":"solvetx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://solvetx.com"},{"fact":"description","publisher":"solvetx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://solvetx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["nginx"],"totalRaisedUsd":321000000,"traction":[],"updatedAt":"2026-06-17","valuations":[]}